Anxiolytic agents are drugs used to depress the central nervous system (CNS) to prevent the signs and symptoms of anxiety. Hypnotic agents are drugs used to depress the CNS to cause sleep. In general, these drugs will induce sleep when given in high doses at night and will provide sedation and reduce anxiety when given in low divided doses during the day.

• Anxiety: An unpleasant feeling of tension, fear, apprehension, or nervousness in response to an environmental stimulus, whether real or imaginary. The physical symptoms of severe anxiety are similar to those of fear (tachycardia, sweating, trembling, palpitations) and involve sympathetic activation.
• Sedative: A drug that depresses the CNS; produces a calming effect, reduces excitement, and produces a loss of awareness of and reaction to the environment. It may induce drowsiness without necessarily inducing sleep.
• Sedation: The loss of awareness of and reaction to environmental stimuli.
• Hypnotic: A drug that induces sleep resembling natural sleep. Both sedation and hypnosis may be considered as different grades of CNS depression.
• Hypnosis: Extreme sedation resulting in CNS depression and sleep.
• Benzodiazepine: A class of drugs that acts in the limbic system and the reticular activating system to make gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, more effective, causing interference with neuron firing; depresses CNS to block the signs and symptoms of anxiety, and may cause sedation and hypnosis in higher doses.
• Barbiturate: A former mainstay drug class used for the treatment of anxiety and for sedation and sleep induction; associated with potentially severe adverse effects and many drug–drug interactions, which makes it less desirable than some of the newer agents.

Sleep is a naturally periodic state of mind and body, characterized by altered consciousness. It is vital for heart health, reducing stress and inflammation, improving memory, weight loss, and maximizing athletic and intellectual performance.

A normal sleep cycle consists of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep.

• NREM Sleep (Non-Rapid Eye Movement): Comprises four stages.
  • Stage 1 (Lightest, 1-7 min): Heartbeat and breathing slow down, muscles relax with occasional twitches, brain waves begin to slow.
  • Stage 2 (Light, 10-25 min): Heartbeat and breathing slow further, body temperature drops, eye movements stop.
  • Stage 3 (Deep sleep, 20-40 min): Heartbeat and breathing reach lowest levels, muscles stay relaxed.
  • Stage 4 (Deepest NREM): Profound CNS depression; restorative sleep.
• REM Sleep (20-40 min): Eyes move rapidly from side to side behind closed eyelids. Breathing speeds up and becomes irregular, heart rate and blood pressure increase. Dreams typically happen during REM sleep.

• Insomnia: A sleep disorder in which you have trouble falling and/or staying asleep. Acute insomnia lasts from 1 night to a few weeks. Chronic insomnia happens at least 3 nights a week for 3 months or more.
• Hyposomnia: Decreased sleep duration.
• Parasomnia: Abnormal behaviors during sleep (e.g., Sleep Terrors, Sleep Walking).
• Sleep Apnea: Breathing repeatedly stops and starts during sleep.
• Narcolepsy: Overwhelming daytime drowsiness and sudden attacks of sleep.
• Other disorders: Restless leg syndrome, Bruxism (teeth grinding), REM sleep behavior disorder.

Benzodiazepines (BDZs)	Barbiturates	Newer Non-BDZ Hypnotics / Others
Long-acting: Diazepam, Flurazepam, Clonazepam, Prazepam, Chlordiazepoxide, Quazepam	Long-acting: Phenobarbital, Mephobarbital, Metharbital	Z-Drugs (Non-BDZ Hypnotics): Zolpidem, Zaleplon, Eszopiclone Anxiolytics: Buspirone, Meprobamate Others: Chloral hydrate, Promethazine, Diphenhydramine, Dexmedetomidine, Ramelteon
Intermediate-acting: Nitrazepam, Lorazepam, Oxazepam, Temazepam, Medazepam, Alprazolam, Estazolam	Intermediate-acting: Amobarbital, Apobarbital, Butabarbital
Short-acting: Triazolam, Midazolam	Short-acting: Pentobarbital, Secobarbital Ultra short-acting: Methohexital, Thiopental, Thiamylal

Benzodiazepines (BDZs) are the most frequently used anxiolytic drugs. They prevent anxiety without causing much associated sedation. In addition, they are less likely to cause physical dependence than many of the older sedatives/hypnotics (like barbiturates) that are used to relieve anxiety.

• GABA is the most potent inhibitory neurotransmitter in the CNS and controls the state of neuronal excitability.
• BDZs act by potentiating the action of the neurotransmitter GABA (gamma-aminobutyric acid).
• They bind selectively to specific subunits of the GABA-A receptors, at a site distinct from where GABA or barbiturates bind, designated as the benzodiazepine binding site.
• Key Feature: Binding of BDZs enhances GABA binding and increases the frequency of chloride channel openings.
• This increases the chloride ion concentration inside the neuron, causing hyperpolarization of the neuronal membrane, making it more difficult for excitatory neurotransmitters to depolarize the cell.
• The primary sites of action appear to be the limbic system (governing emotions) and the reticular activating system (RAS) (which maintains consciousness, sleep, and alertness).

1. Antianxiety Effect: They exert a specific effect on the limbic system, reducing anxiety and producing a calming effect. Alprazolam has additional antidepressant properties.
2. Sedative-Hypnotic Effect: In smaller doses, they cause sedation. In higher doses, they induce sleep (hypnosis). They shorten the time spent in Stage 4 NREM and REM sleep but increase total sleep time. Sleep produced is refreshing with fewer hangover symptoms compared to barbiturates.
3. Anticonvulsant Effect: Long-acting BDZs (Clonazepam) raise the seizure threshold by potentiating GABA. Lorazepam and Diazepam prevent the spread of seizures in the brain.
4. Skeletal Muscle Relaxant: Produce relaxation by facilitating GABAergic transmission in the brainstem and spinal cord. Used in acute spasms caused by trauma or upper motor neuron disorders.
5. Amnesia: BDZs produce anterograde amnesia (loss of memory for events happening after administration). This is highly advantageous during unpleasant surgical or endoscopic procedures.

• Absorption: Well absorbed from the gastrointestinal (GI) tract, with peak levels achieved in 30 minutes to 2 hours.
• Distribution: Highly lipid-soluble; widely distributed throughout the body. They easily cross the blood-brain barrier, cross the placenta, and enter breast milk.
• Metabolism: Metabolized extensively in the liver. Patients with liver disease must receive a smaller dose and be monitored closely.
• Excretion: Primarily excreted through the urine.

• Anxiety Disorders: Panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, performance anxiety, PTSD, OCD, and extreme phobias.
• Sleep Disorders: Used as hypnotic agents for the short-term treatment of insomnia.
• Seizures: Status epilepticus (IV Diazepam or Lorazepam), and in the treatment of alcohol withdrawal to reduce the risk of withdrawal-related seizures (Chlordiazepoxide, Diazepam).
• Muscular Disorders: Skeletal muscle spasms, degenerative disorders like multiple sclerosis and cerebral palsy.
• Preanesthetic / Amnesia: Preoperative relief of anxiety and tension to aid in balanced anesthesia (Midazolam given IM or IV).

• Allergy to any benzodiazepine.
• Psychosis: Could be exacerbated by sedation.
• Acute conditions: Acute narrow-angle glaucoma, shock, coma, or acute alcoholic intoxication (could be lethally exacerbated by CNS depressant effects).
• Pregnancy: Strictly contraindicated. A predictable syndrome of cleft lip/palate, inguinal hernia, cardiac defects, microcephaly, or pyloric stenosis occurs when taken in the first trimester. Neonatal withdrawal syndrome or "floppy infant syndrome" may also result.
• Lactation: Contraindicated because of potential adverse effects on the neonate (e.g., severe sedation).
• Elderly or Debilitated Patients: Use with extreme caution because of the possibility of unpredictable reactions (paradoxical agitation), delayed metabolism leading to accumulation, and increased fall risk. Dose adjustments are required.
• Renal or Hepatic Dysfunction: Alters metabolism and excretion, resulting in direct toxicity.

• CNS Effects: Sedation, drowsiness, depression, lethargy, blurred vision, headaches, apathy, light-headedness, confusion, disorientation, agitation, slurred speech, vertigo, hallucinations, and tremors.
• GI System: Dry mouth, constipation, anorexia, nausea, vomiting, and elevated liver enzymes.
• Cardiovascular System: Hypotension (especially with rapid IV push), bradycardia, palpitations.
• Hematologic: Blood dyscrasias, agranulocytosis, neutropenia, anemia.
• Genitourinary (GU): Urinary retention, incontinence, hesitancy, loss of libido, and changes in sexual functioning.
• Tolerance and Dependence: While present, liability is significantly less than with barbiturates. Abrupt cessation may lead to withdrawal syndrome (nausea, headache, vertigo, malaise, nightmares, and potentially seizures).

• The risk of CNS depression increases significantly if taken with alcohol, barbiturates, opioids, or other CNS depressants. Avoid combinations.
• Effects of BDZs increase (due to inhibited metabolism) if taken with cimetidine, oral contraceptives, or disulfiram.
• Impact may be decreased if given with theophyllines or ranitidine.
• Antidote: Flumazenil (0.1 mg/ml). A competitive benzodiazepine receptor antagonist used for the treatment of overdose.

The barbiturates were once the sedative/hypnotic drugs of choice. However, the likelihood of profound sedation, severe adverse effects, lack of a specific antidote, a narrow therapeutic index, and the high risk of addiction/dependence has caused them to be largely replaced by newer anxiolytic drugs (BDZs).

• Barbiturates depress the sensory and motor activity in the cerebral cortex.
• They act on the reticular activating system (RAS), elevating the firing threshold and depressing the firing rate of neurons.
• They bind selectively to subunits of the GABA-A receptors, at a site distinct from the GABA or BDZ binding site (designated as the Barbiturate binding site).
• Key Feature: Barbiturates potentiate GABA action by prolonging the duration of the chloride channel openings. (At high doses, they can directly open the channel even without GABA).
• This causes profound hyperpolarization of the neuronal membrane and deep CNS depression.

1. Sedation: In low doses, they show drowsiness, calmness, and a sense of well-being (euphoria). Due to depression of the RAS.
2. Hypnosis: Induce sleep in a dose 3 to 4 times higher than the sedative dose. They relieve insomnia by inducing stage 2 of NREM sleep (but suppress REM sleep).
3. General Anesthesia: Ultra-short acting barbiturates (Methohexital, Thiopental) are administered IV for the rapid induction of general anesthesia. They produce reversible loss of consciousness.
4. Anticonvulsant Action: Long-acting barbiturates (Phenobarbital, Mephobarbital) block excess neuronal firing. Indicated in grand mal epilepsy and cortical focal seizures.
5. Respiratory Depression: In large doses, they depress the respiratory center in the medulla oblongata, leading to hypoventilation or fatal apnea.
6. Enzyme Induction: Barbiturates (especially Phenobarbital) powerfully stimulate the functioning of hepatic microsomal enzymes (CYP450 system). This increases the metabolism and decreases the effectiveness of many concomitant drugs.

• Absorbed well, reaching peak levels in 20 to 60 minutes.
• Metabolized heavily in the liver.
• Excreted in the urine. The longer-acting barbiturates (e.g., Phenobarbital) tend to be metabolized slower and excreted to a greater degree unchanged in the urine (making alkalinization of urine an effective treatment for overdose).

• Allergy to any barbiturate.
• Addiction: Previous history of addiction to sedative/hypnotic drugs (barbiturates are highly addictive).
• Porphyria: Strictly contraindicated; barbiturates induce enzymes that synthesize porphyrins, which can trigger a severe, life-threatening acute porphyria attack.
• Hepatic impairment or nephritis: Alters metabolism and excretion, leading to rapid toxicity.
• Severe respiratory dysfunction: Conditions like COPD or severe asthma could be lethally exacerbated by the respiratory depression.
• Pregnancy: Contraindicated because of potential adverse effects on the fetus (depression of fetal respiration during labor) and reported congenital abnormalities.

• Hangover: Due to residual depression of the CNS. Accompanied by headache, nausea, vomiting, vertigo, diarrhea, distortions of mood, and impaired judgment.
• Drug Automatism (Memory Loss): When used as a hypnotic, confusion and amnesia may cause a patient to forget they took the pill, repeatedly take more doses at night, and accidentally poison themselves.
• Tolerance & Dependence: Repeated administration quickly causes tolerance to sedative/hypnotic actions (but NOT to the lethal respiratory depression threshold). High risk of physical and psychological dependence.
• Allergic Reactions: Urticaria, angioneurotic edema, agranulocytosis, thrombocytopenic purpura, serum sickness, and potentially fatal Stevens-Johnson syndrome.
• GI Effects: Nausea, vomiting, epigastric pain.
• CVS Effects: Bradycardia, hypotension (particularly with IV administration), and syncope.

• Profound, synergistic CNS depression if taken with alcohol, antihistamines, or other tranquilizers.
• Altered response to phenytoin when combined with barbiturates.
• MAO Inhibitors increase serum levels and effects of barbiturates.
• Enzyme Induction: Barbiturates accelerate the metabolism of oral anticoagulants (Warfarin), digoxin, TCAs, corticosteroids, oral contraceptives, estrogens, acetaminophen, metronidazole, beta-blockers, griseofulvin, theophyllines, and doxycycline, severely reducing their clinical effectiveness.

Often caused by suicidal attempts or drug automatism. Symptoms include deep CNS depression, respiratory depression, peripheral circulatory collapse, wheezing, hypotension, hypopyrexia, absent reflexes, coma, and potentially death. Fatal complications include atelectasis, pulmonary edema, and pneumonia.

1. Hospitalization & Intensive Care: Immediate admission.
2. Adequate Tissue Oxygenation: Endotracheal intubation is performed when spontaneous respiration is inadequate and to prevent aspiration/remove secretions. If assisted ventilation is required >24 hours, tracheostomy may be performed.
3. Gastric Lavage: If the patient is conscious and < 4 hours have elapsed since ingestion, induce vomiting or use lavage. In comatose patients, endotracheal intubation must precede gastric lavage to prevent aspiration pneumonia.
4. Intravenous Fluids: Given in sufficient quantity to prevent dehydration, maintain blood volume, and support diuresis. Vasopressors (dopamine) used if hypotension persists.
5. Alkalinisation of the Urine: Sodium bicarbonate (50ml of 7.5% solution) is added to IV fluids. Maintaining urinary pH between 7.5 and 8.5 ionizes the barbiturate (a weak acid) in the urine, preventing reabsorption and drastically increasing the excretion of long-acting agents like phenobarbital.
6. Forced Diuresis: Osmotic diuretics (Mannitol 25%) or loop diuretics (Furosemide 20 mg) are administered to aggressively flush the drug through the kidneys.
7. Hemodialysis: About 40 times more effective than forced diuresis in promoting elimination. Highly indicated in severe cardiac/renal impairment where massive fluid loading is contraindicated.
8. Prophylactic Antibiotics: May be necessary for intubated/catheterized patients to prevent secondary infections.

Drug Name	Dosage / Route	Indications & Considerations
BENZODIAZEPINES
Alprazolam (Xanax)	0.25–0.5 mg PO t.i.d. up to 1–10 mg/day; reduce dose in elderly.	Anxiety, panic attacks. Onset: 30 min. Taper after long-term therapy.
Chlordiazepoxide (Librium)	5–25 mg PO t.i.d. to q.i.d.; or 50–100 mg IV or IM.	Anxiety, alcohol withdrawal, preoperative. Duration: 2-3 days. Monitor injection sites.
Clorazepate (Tranxene)	15–60 mg/day in divided doses.	Anxiety, alcohol withdrawal, partial seizures. Taper dosage.
Diazepam (Valium)	Adult: 2–10 mg PO b.i.d. to q.i.d.; or 2–30 mg IM/IV.	Anxiety, alcohol withdrawal, muscle relaxant, antiepileptic. Drug of choice if route change anticipated.
Estazolam (ProSom)	1 mg PO at bedtime.	Hypnotic for insomnia. Monitor liver/renal function long-term.
Flurazepam (Dalmane)	30 mg PO at bedtime (15 mg in elderly).	Hypnotic for insomnia. Long-lasting.
BARBITURATES
Amobarbital (Amytal sodium)	65–500 mg IM or IV.	Sedative-hypnotic, convulsions. Monitor carefully via IV.
Butabarbital (Butisol)	15–30 mg PO t.i.d. to q.i.d.; 50-100 mg at bedtime.	Short-term sedative-hypnotic. May produce excitability in children.
Pentobarbital (Nembutal)	20 mg PO t.i.d. to q.i.d.; 100 mg at bedtime; 150-200 mg IM.	Sedative-hypnotic, preanesthetic. Give IV slowly.
Phenobarbital (Luminal)	30–120 mg/day PO, IM, or IV.	Long-acting. Seizure control, sedation. Highly effective for grand mal.
Secobarbital (Seconal)	100–300 mg PO.	Preanesthetic, acute convulsive seizures (tetanus). Rapid onset.
OTHER ANXIOLYTICS & HYPNOTICS
Buspirone (BuSpar)	Oral drug for anxiety.	Lacks sedative, anticonvulsant, and muscle-relaxant properties. No dependence. May cause dry mouth/headache. Takes weeks to reach full effect.
Zolpidem (Ambien)	Oral drug for short-term insomnia.	Z-Drug. Binds selectively to BDZ receptor subtype (Alpha-1). No anticonvulsant/muscle relaxing properties. Minimal rebound insomnia. Withdraw gradually.
Zaleplon (Sonata)	Oral for short-term insomnia.	Similar to Zolpidem. Take right before bed (devote 4-8 hours to sleep).
Eszopiclone (Lunesta)	Oral for insomnia.	Tablet must be swallowed whole. Allow 8 h for sleep.
Diphenhydramine (Benadryl) / Promethazine	PO, IM, or IV.	Antihistamines. Highly sedating. Used as sleep aids or pre-op. Monitor for thickened respiratory secretions (anticholinergic drying effect).
Chloral Hydrate	PO or PR.	Nocturnal sedation, preoperative sedation. Withdraw gradually over 2 weeks.
Ramelteon (Rozerem)	Oral.	Melatonin receptor agonist. For difficulty falling asleep. Take 30 min before bed.
Meprobamate (Miltown)	Oral.	Short-term management of anxiety. High risk of addiction.
Dexmedetomidine (Precedex)	IV.	Used for newly intubated/ventilated patients in ICU. Alpha-2 agonist. Do not use longer than 24h.

• Parenteral Administration Rules: Do not administer intra-arterially (causes severe arteriospasm and gangrene). Monitor injection sites carefully for phlebitis. Give IV drugs very slowly because rapid administration is associated with hypotension, bradycardia, and cardiac arrest. Do not mix IV drugs in solution with other drugs to avoid precipitation and interactions.
• Transitioning Therapy: Give parenteral forms only if oral forms are not feasible, and switch to oral forms (which are safer and have fewer adverse effects) as soon as possible.
• Narcotic Adjustments: Arrange to reduce the dose of narcotic analgesics in patients receiving a benzodiazepine or barbiturate to decrease potentiated CNS and respiratory depression.
• Mobility and Safety: Maintain patients who receive parenteral agents in bed for at least 3 hours. Do not permit ambulatory patients to operate a motor vehicle or heavy machinery. Institute fall precautions (side rails, assistance with ambulation).
• Long-Term Monitoring: Monitor hepatic and renal function, as well as CBC, during long-term therapy to detect dysfunction. If noted, arrange to taper and discontinue the drug.
• Withdrawal Prevention: Never abruptly stop long-term therapy. Taper dose gradually, especially in epileptic patients. Acute withdrawal could precipitate fatal status epilepticus or severe withdrawal syndrome.
• Comfort Measures: Have patients void before dosing. Institute a bowel program as needed. Give food with the drug if GI upset is severe. Provide environmental control (dim lighting, quiet room, temperature regulation) to enhance sleep hygiene and drug efficacy.
• Patient Education: Provide thorough teaching including the drug name, prescribed dose, avoidance of alcohol and OTC depressants, warning signs of toxicity, and the need for periodic lab monitoring to promote compliance.
• Emergency Preparedness: Always provide standby life-support facilities (resuscitation equipment, intubation tray) in case of severe respiratory depression or hypersensitivity reactions. Keep the antidote (Flumazenil) readily available for BDZ overdoses.

No.	Nursing Diagnosis	Intervention / Rationale
1	Risk for Injury / Falls related to central nervous system depression, drowsiness, ataxia, and confusion.	Implement rigorous fall precautions. Instruct the patient to call for assistance before getting out of bed. Keep the bed in the lowest position with side rails up. CNS depressants impair motor coordination and judgment, dramatically increasing fall risk, especially in the elderly.
2	Impaired Gas Exchange / Ineffective Breathing Pattern related to dose-dependent respiratory depression (particularly with IV barbiturates/BDZs).	Continuously monitor respiratory rate, depth, and oxygen saturation. Maintain an open airway. Have emergency airway equipment nearby. These agents depress the medullary respiratory center. Hypoxia and hypercapnia can occur rapidly, leading to respiratory arrest.
3	Deficient Knowledge regarding safe drug usage, avoidance of interactions (alcohol), and withdrawal risks.	Educate the patient to strictly avoid alcohol and unprescribed antihistamines. Teach the importance of not abruptly stopping the medication. Combining CNS depressants is synergistic and potentially fatal. Abrupt cessation leads to rebound nervous system hyperactivity and seizures.
4	Disturbed Sleep Pattern related to underlying anxiety, medication "hangover" effect, or REM sleep rebound.	Teach proper sleep hygiene (avoiding caffeine/screens at night). Assess the effectiveness of the hypnotic agent. Reassure the patient that vivid dreams may occur upon discontinuation. While these drugs induce sleep, they alter the natural sleep architecture. REM rebound causes intense nightmares when the drug is stopped.

• Deore, A. B. (n.d.). Sedative, Hypnotic and Anxiolytic Drugs [PDF Presentation slides]. MVP’s Institute of Pharmaceutical Sciences, Nashik.
• Katzung, B. G. (2017). Basic & Clinical Pharmacology (14th ed.). McGraw-Hill Education.
• Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2017). Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education.
• Karch, A. M. (2019). Focus on Nursing Pharmacology (8th ed.). Wolters Kluwer.